Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Study of the Safety and Bioequivalence of Par's Pimecrolimus Cream, 1% and RLD Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis

NCT03297502 is registered in ClinicalTrials.gov with Par Pharmaceutical, Inc. as lead sponsor.

NCT NCT03297502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03297502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Study of the Safety and Bioequivalence of Par's Pimecrolimus Cream, 1% and RLD Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis
Lead sponsor
Par Pharmaceutical, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2016
Completion date
June 30, 2017
Enrollment
582 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis